Lilly Global Health Partnerships – Partners and Approach
UNICEF - In early 2022, Lilly and UNICEF announced a collaboration to help improve health for 10 million children and adolescents living with or at risk of chronic NCDs through 2025*. Lilly has committed $14.4 million in support of UNICEF’s life-saving work to address NCD risk factors, strengthen health systems and enhance the ability of health care workers to care for people in Bangladesh, Malawi, Nepal, the Philippines and Zimbabwe. The countries were selected based on the potential to strengthen country-level health systems and models that provide care and support for children and adolescents with chronic conditions, including type 1 diabetes, cancer, congenital and rheumatic heart disease, sickle cell disease and asthma. More than 500,000 people were impacted through UNICEF’s work during 2022, including clinicians, community health workers (CHWs), district trainers, caregivers, children and adolescents. This four-year commitment reflects the respective efforts of Lilly and UNICEF to work toward the EXTERNAL:UN Sustainable Development Goals, specifically, SDG3, which aims to ensure healthy lives and promote well-being for all at all ages.
AMPATH - Lilly and the Lilly Foundation have each provided support to the Academic Model Providing Access to Healthcare (AMPATH), which has been working for 30 years in western Kenya to improve health for people with limited resources. Lilly’s product donations in support of AMPATH Kenya total $215 million – including $29 million in medicines in 2022 – and are helping people living with cancer, diabetes and mental health disorders. Since 2017, the Lilly Foundation has supported AMPATH’s Breast and Cervical Cancer Control Program, which has far surpassed its original targets for offering early screenings and connecting people with cancer care as appropriate. Most recently, Lilly and the Lilly Foundation provided support to AMPATH’s efforts to establish new health partnerships in Puebla, Mexico, and Tamale, Ghana, which have the potential to reach more than 14 million people by 2030. Lilly has committed support of more than $2.8 million to help establish AMPATH in Puebla. The Lilly Foundation awarded $600,000 for efforts to provide additional personnel in Ghana and $520,000 to support the IU Center for Global Health Equity as the coordinating secretariat of the global AMPATH Consortium of 15 academic health centers from around the world.
Life for a Child - Since 2009, Lilly has provided more than 5.2 million vials and cartridges of insulin to support the Life for a Child program. Life for a Child provides diabetes support to children and youth with diabetes in settings with limited resources. That support includes insulin, delivery devices, monitoring supplies, medical care, diabetes education, complications screening and management, and advocacy. In 2021, Lilly announced plans to expand our support for Life for a Child and increase access to care to approximately 150,000 children and youth annually by the year 2030. To facilitate the expanded support, we have increased our contribution of mealtime and basal insulins and reusable pens, as well as financial support for the costs associated with storing, packing and shipping to countries in collaboration with Direct Relief.
Cold-Chain Collaboration - In early 2023, Lilly and Direct Relief announced a new initiative by Direct Relief with the support of Lilly to expand access to medicines in low- and middle-income countries by expanding medical cold chain capacity in 20 countries. With Lilly’s $1.15 million funding, Direct Relief will procure 191 refrigeration units for 25 Life for a Child supported medical facilities in Africa, Latin America, the Caribbean and South Asia. In addition to supporting Life for a Child, this initiative will strengthen healthcare systems by increasing cold-chain storage so that more healthcare facilities will have the ability to store other cold-chain pharmaceuticals such as injectable therapies, cancer products or vaccines.
Health Worker Training Initiative (HWTI) – As part of the Gates CEO Roundtable, Lilly, along with four other healthcare companies, have supported the HWTI since 2020. Part of The Audacious Project, the HWTI has trained thousands of community health workers (CHWs) in seven African countries – Burkina Faso, Ethiopia, Kenya, Liberia, Malawi, Sierra Leone, and Uganda – to provide life changing services to underserved communities. Implementation partners Last Mile Health and Living Goods have partnered with governments in these countries and shown that, when provided with the necessary training and digital tools, CHWs can bring accessible, affordable and high-quality health care to communities in need.
Tshwane Insulin Project (TIP) – Lilly has partnered with the University of Pretoria in South Africa to support a research project aimed at initiating and titrating insulin in type 2 diabetes patients in primary care. Led by nurses, supported by CHWs and doctors, TIP has proven that patients can be safely initiated on insulin in primary care settings. Interim results show that patients on the TIP program have reached reductions in HbA1C in excess of 2%, bringing them closer to optimal glycemic control. In addition, through TIP hundreds of healthcare workers have been empowered and capacitated to better manage diabetes and hypertension patients.
Noncommunicable Disease (NCD) Link – Recognizing the strong infectious disease infrastructure in place in some LMICs, the NCD-Link project in Durban, South Africa, in partnership with Advance Access and Delivery and the South African Medical Research Council (SAMRC) has used TB as an entry point to start screening patients and their contacts for diabetes and hypertension in clinics and patient households. The project uses an improved diagnostic algorithm aligned with national guidelines for treatment, support and education of patients and families with diabetes and hypertension.
Linkage to Care (LTC) – Similar to the NCD-Link Project in South Africa, the LTC project in Chennai, India, uses an integrated approach to provide comprehensive screening for NCDs like diabetes and hypertension, with TB as an entry point across 40 centers in Chennai. The goal of the project is to screen more patients and family members and connect them with comprehensive and integrated NCD care and raising the general community awareness about NCDs and treatment management.
Gestational Diabetes in Mexico – Lilly is collaborating with the Carlos Slim Foundation and the Mexican Society for Public Health on a five-year effort to improve outcomes for pregnant women with gestational diabetes and their babies. Through the collaboration, we are working to find a less expensive and better way to perform an oral glucose tolerance test to screen for gestational diabetes and help women who test positive avoid complications throughout their pregnancy. The partnership has delivered several important outcomes, including documenting the prevalence of gestational diabetes in Mexico (14%) for the first time at the national level, identifying three subtypes of the disease, and developing a simpler version of the oral glucose tolerance test. In 2022, more than 690,000 people benefited from the educational, diagnosis and improved care through this program.
Expanding One-Stop-Shop Diabetes Care Model across Mexico and U.S. – Lilly is working with Clinicas del Azúcar (Sugar Clinics) and MIT on a six-year effort to validate and expand a comprehensive diabetes care model and related efforts that engage underserved patients in improving their health over the long term. The efficacy of the model of care has been validated, and Clinicas del Azucar has leveraged this evidence to significantly expand the number of clinics and people served across Mexico with 37 clinics and close to 300,000 beneficiaries to date. In the coming year, Lilly is supporting Clinicas del Azucar’s model for further expansion into the United States to provide low-cost improved diabetes management and care with the potential to reach 1 million vulnerable Latinx patients by 2030 and in Texas and other border states.
Diabetes Impact Project – Indianapolis Neighborhoods (DIP-IN) – In 2021, Lilly announced expansion of our support of DIP-IN, committing an additional $5 million to the project led by the Indiana University Richard M. Fairbanks School of Public Health at IUPUI, along with organizational and resident partners. DIP-IN was initially launched in 2018, with a $7 million commitment with the goal of improving diabetes diagnosis, care and overall quality of life in three Indianapolis communities that experience disproportionately high rates of diabetes prevalence compared to the country, state and nation.
The program employs a holistic approach to address diabetes prevention and control in communities where the residents are predominately people of color. Resident steering committees lead the efforts to improve overall quality of life through the support of neighborhood health promotion initiatives. The project includes neighborhood and clinic-based community health workers who help identify people with or at risk for developing diabetes and connect them with quality care.
Global Health partnerships, like DIP-IN, help underscore the unique and powerful role that Community Health Workers (CHWs) play in the health care system. To this end, Lilly is collaborating with GCI Health, a global integrated communications agency, to convene a CHW Policy Forum comprised of key local, state and national organizations, who are steeped in CHW and public health policy. The CHW Policy Forum strives to elevate the essential role of CHWs as part of a resilient health care system and helps shape a policy agenda that supports the long-term sustainability of the CHW workforce.
Direct Relief Fund for Health Equity – In 2021, we announced our commitment of $5 million over five years to Direct Relief’s Fund for Health Equity. Lilly’s commitment to the Direct Relief Fund for Health Equity is a component of our Racial Justice Commitment. Through this fund, U.S. health centers, free and charitable clinics, and other community-based organizations and educational institutions are offered the opportunity to apply for grants from Direct Relief of up to $250,000 annually. Direct Relief makes grants aimed at strengthening the capacity of recipient organizations to provide high-quality, culturally appropriate health care while focusing on social determinants of health for the underserved populations they serve. Lilly’s funding was distributed to four awardees in 2021 and an additional four awardees in 2022.
* UNICEF does not endorse any company, brand, product or service.
See important information about our ESG report.